N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide

CAS : 33288-71-0

Ref. 3D-FA150607

Informations sur le produit

• Nom: N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
• Synonymes: 2-pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-, 4-[2-(5-Methyl-2-pyrazine carboxamido)ethyl]benzene sulfonamide, 4-[2-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide, 4-[2-(5-Methylpyrazinyl-2-carboxamido)ethyl]benzenesulfonamide, 5-Methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide, N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide, Pyrazinecarboxamide, 5-methyl-N-(p-sulfamoylphenethyl)-, Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
• CAS: 33288-71-0

Description

Fluoxetine is a potent inhibitor of the enzyme cytochrome P450 (CYP) 2C19. The inhibition of CYP2C19 by fluoxetine may lead to an increase in the plasma concentration of other drugs that are metabolized by this enzyme, such as glipizide and hydroxycyclohexyl. Fluoxetine inhibits human uric acid secretion and increases plasma concentrations of uric acid. This drug also inhibits human erythrocyte dihydropyrimidine dehydrogenase, leading to increased blood levels of pyrimidines, especially cytotoxic ones like 6-fluoro-3-indoxyl-beta-D-galactopyranoside. Fluoxetine has been shown to have a protective effect against acetaminophen toxicity in rats because it enhances the conversion of acetaminophen to its less toxic metabolite N-acetylcysteine.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 320.37 g/mol
• Formule: C₁₄H₁₆N₄O₃S
• Degré de pureté: Min. 95%
• Couleur/Forme: White To Off-White Solid
• InChI: InChI=1S/C14H16N4O3S/c1-10-8-18-13(9-17-10)14(19)16-7-6-11-2-4-12(5-3-11)22(15,20)21/h2-5,8-9H,6-7H2,1H3,(H,16,19)(H2,15,20,21)
• Code InChI: InChIKey=IMEZLHZLIANIAS-UHFFFAOYSA-N
• SMILES: Cc1cnc(C(=O)NCCc2ccc(S(N)(=O)=O)cc2)cn1